MLi-2 - ≥98%, high purity , CAS No.1627091-47-7, Inhibitor of leucine rich repeat kinase 2

Item Number

M276039

Grouped product items
SKU	Size	Availability	Price
M276039-1mg	1mg	In stock	$49.90
M276039-5mg	5mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$119.90
M276039-10mg	10mg	In stock	$189.90
M276039-50mg	50mg	In stock	$659.90

Potent and selective LRRK2 inhibitor

View related series

Basic Description

Synonyms	(2R,6S)-2,6-Dimethyl-4-[6-[5-(1-methylcyclopropyl)oxy-1H-indazol-3-yl]pyrimidin-4-yl]morpholine;cis-2,6-Dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl)pyrimidin-4-yl)morpholine;rel-3-[6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-4-pyrimidinyl]-5-[(1-me
Specifications & Purity	≥98%
Biochemical and Physiological Mechanisms	Highly effective and selective LRRK2 inhibitors. Inhibition of LRRK2 in cell-free (IC 50 = 0.76 NM) , dephosphorylated cells (IC 50 = 1.4 nM) and radioligand binding (IC 50 = 3.4 nM) assay.
Storage Temp	Store at -20°C
Shipped In	Ice chest + Ice pads
Grade	Moligand™
Action Type	INHIBITOR
Mechanism of action	Inhibitor of leucine rich repeat kinase 2
Note	Refer to SDS for further information. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description	MLi-2 is a structurally novel, highly potent, and selective LRRK2 kinase inhibitor with central nervous system activity. MLi-2 exhibits exceptional potency in a purified LRRK2 kinase assay in vitro (IC50 = 0.76 nM), a cellular assay monitoring dephosphorylation of LRRK2 pSer935 LRRK2 (IC50 = 1.4 nM), and a radioligand competition binding assay (IC50 = 3.4 nM).

Names and Identifiers

IUPAC Name	(2R,6S)-2,6-dimethyl-4-[6-[5-(1-methylcyclopropyl)oxy-1H-indazol-3-yl]pyrimidin-4-yl]morpholine
INCHI	InChI=1S/C21H25N5O2/c1-13-10-26(11-14(2)27-13)19-9-18(22-12-23-19)20-16-8-15(28-21(3)6-7-21)4-5-17(16)24-25-20/h4-5,8-9,12-14H,6-7,10-11H2,1-3H3,(H,24,25)/t13-,14+
InChi Key	ATUUNJCZCOMUKD-OKILXGFUSA-N
Canonical SMILES	CC1CN(CC(O1)C)C2=NC=NC(=C2)C3=NNC4=C3C=C(C=C4)OC5(CC5)C
Isomeric SMILES	C[C@@H]1CN(C[C@@H](O1)C)C2=NC=NC(=C2)C3=NNC4=C3C=C(C=C4)OC5(CC5)C
PubChem CID	78319901
Molecular Weight	379.46

Certificates

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

5 results found

Lot Number	Certificate Type	Date	Item
G2412495	Certificate of Analysis	Jul 02, 2024	M276039
G2412496	Certificate of Analysis	Jul 02, 2024	M276039
B2215423	Certificate of Analysis	Aug 10, 2023	M276039
B2215424	Certificate of Analysis	Aug 10, 2023	M276039
B2215430	Certificate of Analysis	Aug 10, 2023	M276039

References

1. Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong DE, Ellis JM, Hyde LA, Lin Y, Markgraf CG, Mei H et al.. (2015) MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.. J Pharmacol Exp Ther, 355 (3): (397-409). [PMID:26407721]
2. Scott JD, DeMong DE, Greshock TJ, Basu K, Dai X, Harris J, Hruza A, Li SW, Lin SI, Liu H et al.. (2017) Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.. J Med Chem, 60 (7): (2983-2992). [PMID:28245354]
3. Fdez E et al.. (2022) Pathogenic LRRK2 regulates centrosome cohesion via Rab10/RILPL1-mediated CDK5RAP2 displacement.. iScience, 25 (6): (104476). [PMID:35721463]

Solution Calculators

Determine the necessary mass, volume, or concentration for preparing a solution.

Determine the dilution needed to prepare a stock solution.

Basic Description